198 related articles for article (PubMed ID: 38482176)
21. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
Baum P; Visvanathan S; Garcet S; Roy J; Schmid R; Bossert S; Lang B; Bachelez H; Bissonnette R; Thoma C; Krueger JG
J Allergy Clin Immunol; 2022 Apr; 149(4):1402-1412. PubMed ID: 34678325
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis of Generalized Pustular Psoriasis.
Fujita H; Gooderham M; Romiti R
Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):31-38. PubMed ID: 35061226
[TBL] [Abstract][Full Text] [Related]
23. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion.
Bachelez H; Barker J; Burden AD; Navarini AA; Krueger JG
Expert Rev Clin Immunol; 2022 Oct; 18(10):1033-1047. PubMed ID: 36062811
[TBL] [Abstract][Full Text] [Related]
24. Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management.
Puig L; Choon SE; Gottlieb AB; Marrakchi S; Prinz JC; Romiti R; Tada Y; von Bredow D; Gooderham M
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):737-752. PubMed ID: 36606566
[TBL] [Abstract][Full Text] [Related]
25. A brief guide to pustular psoriasis for primary care providers.
Crowley JJ; Pariser DM; Yamauchi PS
Postgrad Med; 2021 Apr; 133(3):330-344. PubMed ID: 33118424
[TBL] [Abstract][Full Text] [Related]
26. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review.
Kharawala S; Golembesky AK; Bohn RL; Esser D
Expert Rev Clin Immunol; 2020 Mar; 16(3):239-252. PubMed ID: 32073341
[No Abstract] [Full Text] [Related]
27. Current management of generalized pustular psoriasis.
Kodali N; Blanchard I; Kunamneni S; Lebwohl MG
Exp Dermatol; 2023 Aug; 32(8):1204-1218. PubMed ID: 36779681
[TBL] [Abstract][Full Text] [Related]
28. Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
Megna M; Camela E; Ruggiero A; Battista T; Martora F; Cacciapuoti S; Potestio L
Clin Cosmet Investig Dermatol; 2023; 16():1677-1690. PubMed ID: 37404368
[TBL] [Abstract][Full Text] [Related]
29. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM; Mohammad NA; Nanu NM; Tey KE; Chew SF
Int J Dermatol; 2014 Jun; 53(6):676-84. PubMed ID: 23967807
[TBL] [Abstract][Full Text] [Related]
30. A review of disease burden and clinical management for generalized pustular psoriasis in China.
Lu J; Shi Y
Expert Rev Clin Immunol; 2022 Oct; 18(10):1023-1032. PubMed ID: 36040447
[TBL] [Abstract][Full Text] [Related]
31. Spesolimab: A Review of the First IL-36 Blocker Approved for Generalized Pustular Psoriasis.
Pathak GN; Wang E; Dhillon J; Parikh PN; Esseghir R; Rao BK; Feldman SR
Ann Pharmacother; 2024 May; ():10600280241252688. PubMed ID: 38755971
[TBL] [Abstract][Full Text] [Related]
32. Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis.
Shao S; Wang G
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2627-2635. PubMed ID: 36208408
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation.
Potestio L; Camela E; Cacciapuoti S; Martora F; Guerriero L; Fornaro L; Ruggiero A; Megna M
Expert Opin Drug Saf; 2023; 22(11):1003-1010. PubMed ID: 37768729
[TBL] [Abstract][Full Text] [Related]
34. Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients.
Bukhari T; Markovina M; Abduelmula A; Rankin BD; Vender R; Yeung J; Devani AR; Prajapati VH
Skin Therapy Lett; 2024 Jan; 29(1):1-4. PubMed ID: 38271532
[TBL] [Abstract][Full Text] [Related]
35. Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists.
Strober B; Kotowsky N; Medeiros R; Mackey RH; Harrold LR; Valdecantos WC; Flack M; Golembesky AK; Lebwohl M
Dermatol Ther (Heidelb); 2021 Apr; 11(2):529-541. PubMed ID: 33638115
[TBL] [Abstract][Full Text] [Related]
36. Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey.
Reisner DV; Johnsson FD; Kotowsky N; Brunette S; Valdecantos W; Eyerich K
Am J Clin Dermatol; 2022 Jan; 23(Suppl 1):65-71. PubMed ID: 35061229
[TBL] [Abstract][Full Text] [Related]
37. Incidence and prevalence of generalized pustular psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using routinely captured electronic health records in the Teleprimary Care (TPC®) clinical information system from 2010 to 2020.
Choon SE; Wright AK; Griffiths CEM; Wong KW; Tey KE; Lim YT; Chua KY; Ashcroft DM
Br J Dermatol; 2023 Sep; 189(4):410-418. PubMed ID: 37162007
[TBL] [Abstract][Full Text] [Related]
38. Clinical advances in biological therapy for generalized pustular psoriasis: a review.
Hsieh CY; Tsai TF
Expert Opin Biol Ther; 2024; 24(1-2):37-50. PubMed ID: 38247394
[TBL] [Abstract][Full Text] [Related]
39. Generalized pustular psoriasis: current management status and unmet medical needs in Japan.
Komine M; Morita A
Expert Rev Clin Immunol; 2021 Sep; 17(9):1015-1027. PubMed ID: 34402355
[TBL] [Abstract][Full Text] [Related]
40. Understanding Flares in Patients With Generalized Pustular Psoriasis Documented in US Electronic Health Records.
Zema CL; Valdecantos WC; Weiss J; Krebs B; Menter AM
JAMA Dermatol; 2022 Oct; 158(10):1142-1148. PubMed ID: 35947363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
